Heparin preserves antithrombin III biological activity from hyperglycemia-induced alterations in insulin-dependent diabetics

A. Ceriello, D. Giugliano, A. Quatraro, A. Stante, G. Consoli, P. Dello Russo, F. D'Onofrio

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Alteration in antithrombin III (ATIII) biological activity, despite its normal plasma concentration, in diabetic subjects is shown in this report. This alteration is glycemia level-dependent, there existing an inverse correlation between fluctuations of daily blood glucose level, labile glycosylated hemoglobin and ATIII activity. The subcutaneous and endovenous heparin administration restores ATIII activity, but does not modify its plasma concentration in diabetics. Moreover, heparin treatment preserves ATIII activity from glycemia-induced alterations. These data suggest a role for glucose, probably through a labile nonenzymatic glycation process, in determining the alteration of ATIII biological activity. Moreover, showing the possibility by heparin administration to restore ATIII activity and preserve its biological function from effects of glycemia variations, stress the hypothesis that glucose and heparin compete in vivo, both against the same catalytic residue of ATIII.

Original languageEnglish
Pages (from-to)458-464
Number of pages7
JournalHaemostasis
Volume16
Issue number6
Publication statusPublished - 1986

Fingerprint

Antithrombin III
Hyperglycemia
Heparin
Insulin
Glucose
Glycosylated Hemoglobin A
Blood Glucose

ASJC Scopus subject areas

  • Hematology

Cite this

Ceriello, A., Giugliano, D., Quatraro, A., Stante, A., Consoli, G., Dello Russo, P., & D'Onofrio, F. (1986). Heparin preserves antithrombin III biological activity from hyperglycemia-induced alterations in insulin-dependent diabetics. Haemostasis, 16(6), 458-464.

Heparin preserves antithrombin III biological activity from hyperglycemia-induced alterations in insulin-dependent diabetics. / Ceriello, A.; Giugliano, D.; Quatraro, A.; Stante, A.; Consoli, G.; Dello Russo, P.; D'Onofrio, F.

In: Haemostasis, Vol. 16, No. 6, 1986, p. 458-464.

Research output: Contribution to journalArticle

Ceriello, A, Giugliano, D, Quatraro, A, Stante, A, Consoli, G, Dello Russo, P & D'Onofrio, F 1986, 'Heparin preserves antithrombin III biological activity from hyperglycemia-induced alterations in insulin-dependent diabetics', Haemostasis, vol. 16, no. 6, pp. 458-464.
Ceriello, A. ; Giugliano, D. ; Quatraro, A. ; Stante, A. ; Consoli, G. ; Dello Russo, P. ; D'Onofrio, F. / Heparin preserves antithrombin III biological activity from hyperglycemia-induced alterations in insulin-dependent diabetics. In: Haemostasis. 1986 ; Vol. 16, No. 6. pp. 458-464.
@article{24c1c0bf48bc499795b453bb9cde0393,
title = "Heparin preserves antithrombin III biological activity from hyperglycemia-induced alterations in insulin-dependent diabetics",
abstract = "Alteration in antithrombin III (ATIII) biological activity, despite its normal plasma concentration, in diabetic subjects is shown in this report. This alteration is glycemia level-dependent, there existing an inverse correlation between fluctuations of daily blood glucose level, labile glycosylated hemoglobin and ATIII activity. The subcutaneous and endovenous heparin administration restores ATIII activity, but does not modify its plasma concentration in diabetics. Moreover, heparin treatment preserves ATIII activity from glycemia-induced alterations. These data suggest a role for glucose, probably through a labile nonenzymatic glycation process, in determining the alteration of ATIII biological activity. Moreover, showing the possibility by heparin administration to restore ATIII activity and preserve its biological function from effects of glycemia variations, stress the hypothesis that glucose and heparin compete in vivo, both against the same catalytic residue of ATIII.",
author = "A. Ceriello and D. Giugliano and A. Quatraro and A. Stante and G. Consoli and {Dello Russo}, P. and F. D'Onofrio",
year = "1986",
language = "English",
volume = "16",
pages = "458--464",
journal = "Haemostasis",
issn = "0301-0147",
publisher = "S. Karger AG",
number = "6",

}

TY - JOUR

T1 - Heparin preserves antithrombin III biological activity from hyperglycemia-induced alterations in insulin-dependent diabetics

AU - Ceriello, A.

AU - Giugliano, D.

AU - Quatraro, A.

AU - Stante, A.

AU - Consoli, G.

AU - Dello Russo, P.

AU - D'Onofrio, F.

PY - 1986

Y1 - 1986

N2 - Alteration in antithrombin III (ATIII) biological activity, despite its normal plasma concentration, in diabetic subjects is shown in this report. This alteration is glycemia level-dependent, there existing an inverse correlation between fluctuations of daily blood glucose level, labile glycosylated hemoglobin and ATIII activity. The subcutaneous and endovenous heparin administration restores ATIII activity, but does not modify its plasma concentration in diabetics. Moreover, heparin treatment preserves ATIII activity from glycemia-induced alterations. These data suggest a role for glucose, probably through a labile nonenzymatic glycation process, in determining the alteration of ATIII biological activity. Moreover, showing the possibility by heparin administration to restore ATIII activity and preserve its biological function from effects of glycemia variations, stress the hypothesis that glucose and heparin compete in vivo, both against the same catalytic residue of ATIII.

AB - Alteration in antithrombin III (ATIII) biological activity, despite its normal plasma concentration, in diabetic subjects is shown in this report. This alteration is glycemia level-dependent, there existing an inverse correlation between fluctuations of daily blood glucose level, labile glycosylated hemoglobin and ATIII activity. The subcutaneous and endovenous heparin administration restores ATIII activity, but does not modify its plasma concentration in diabetics. Moreover, heparin treatment preserves ATIII activity from glycemia-induced alterations. These data suggest a role for glucose, probably through a labile nonenzymatic glycation process, in determining the alteration of ATIII biological activity. Moreover, showing the possibility by heparin administration to restore ATIII activity and preserve its biological function from effects of glycemia variations, stress the hypothesis that glucose and heparin compete in vivo, both against the same catalytic residue of ATIII.

UR - http://www.scopus.com/inward/record.url?scp=0022918520&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022918520&partnerID=8YFLogxK

M3 - Article

C2 - 3583099

AN - SCOPUS:0022918520

VL - 16

SP - 458

EP - 464

JO - Haemostasis

JF - Haemostasis

SN - 0301-0147

IS - 6

ER -